<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919787</url>
  </required_header>
  <id_info>
    <org_study_id>NorPACT-1</org_study_id>
    <secondary_id>2015-001635-21</secondary_id>
    <nct_id>NCT02919787</nct_id>
  </id_info>
  <brief_title>Nordic Pancreatic Cancer Trial (NorPACT) - 1</brief_title>
  <official_title>Nordic Multicentre Un-blinded Phase II Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the additional effect of adding chemotherapy prior to resection of a&#xD;
      pancreatic head malignancy. The patients will be randomized into two groups; surgery first&#xD;
      (control group) and neoadjuvant chemotherapy (intervention). Primary endpoint is overall&#xD;
      survival after resection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is the fourth leading cause of cancer-related deaths in Europe and the&#xD;
      United States. Surgical resection remains the only potentially curative treatment. However,&#xD;
      the median survival of patients undergoing pancreatic resection alone is 16-23 months. The&#xD;
      administration of adjuvant chemotherapy leads to an improvement in overall survival. Thus,&#xD;
      completion of multimodality treatment (MMT) is the ideal goal and standard of care for&#xD;
      treatment of pancreatic ductal adenocarcinoma (PDAC).&#xD;
&#xD;
      Currently, the surgery-first (SF) strategy is the most universally accepted approach to&#xD;
      resectable PDAC (and is the standard of care in Norway), but the optimal sequence of surgery&#xD;
      and chemotherapy remains unclear.&#xD;
&#xD;
      The purpose of this study is to further investigate the additional efficacy of neoadjuvant&#xD;
      chemotherapy to the standard treatment for resectable cancer of the pancreatic head (surgery&#xD;
      followed by adjuvant chemotherapy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival 18 month after randomization</measure>
    <time_frame>18 month</time_frame>
    <description>Overall survival at 18 months after date of randomization (intention to treat)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality at one year following commencement of allocated treatment.</measure>
    <time_frame>1 year</time_frame>
    <description>Overall mortality at one year following commencement of allocated treatment (NT or SF) for those who ultimately undergo resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>until 5 years after surgery</time_frame>
    <description>Patient will come to regular after surgery for follow-up visits regarding their disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological response</measure>
    <time_frame>Arm 1: Baseline and Arm 2; 4 weeks after baseline</time_frame>
    <description>The histopathological response of the tumor to the neoadjuvant treatment will be assessed by established scores (R0 resection and (y)pN0 disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate after surgery</measure>
    <time_frame>30 and 90 days</time_frame>
    <description>Complication rate after surgery as measured by Dindo-Clavien/ISPGS classification systems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of neoadjuvant and adjuvant chemotherapy</measure>
    <time_frame>Baseline</time_frame>
    <description>The feasibility of neo-adjuvant and adjuvant chemotherapy measured by common Terminology Criteria for Adverse Events, grade 3-5, dose reduction and dose delay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life</measure>
    <time_frame>until 5 years after surgery</time_frame>
    <description>Data of quality of life will be assessed by the questionnaires EORTC QLQ-30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics</measure>
    <time_frame>until 5 years after surgery</time_frame>
    <description>Data of quality of life will be assessed by the questionnaires EQ-5D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery and then postoperative adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatine</intervention_name>
    <description>Neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatic surgery</intervention_name>
    <description>All patients</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Adjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatine</intervention_name>
    <description>Adjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Adjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Resectable adenocarcinoma of the pancreatic head&#xD;
&#xD;
          -  T1-3, Nx, M0 (UICC 7th version, 2010)&#xD;
&#xD;
          -  Cytologic or histologic confirmation of adenocarcinoma&#xD;
&#xD;
          -  Age &gt; 18 year and considered fit for major surgery&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Considered able to receive the study specific chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-morbidity precluding pancreaticoduodenectomy&#xD;
&#xD;
          -  Chronic neuropathy ≥ grade 2&#xD;
&#xD;
          -  WHO performance score &gt; 2 • Granulocyte count &lt; 1500 per cubic millimetre&#xD;
&#xD;
          -  Platelet count &lt; 100 000 per cubic millimeter&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 UNL (upper limit normal range)&#xD;
&#xD;
          -  Albumin &lt; 2,5 g/dl&#xD;
&#xD;
          -  Female patients in child bearing age not using adequate contraception, pregnant or&#xD;
             lactating women • Mental or organic disorders which could interfere with informed&#xD;
             consent or treatments&#xD;
&#xD;
          -  Other malignancy within the past 5 years, except non-melanomatous skin or non-invasive&#xD;
             cervical cancer&#xD;
&#xD;
          -  Percutaneous tumor biopsy&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not participate&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut Jorgen Labori, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Per Pfeiffer</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ville Sallinen</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N- 0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tromsø University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olav University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Huddinge</city>
        <zip>14157</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <zip>90737</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Knut Jørgen Labori</investigator_full_name>
    <investigator_title>Senior Consultant HPB-surgery</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

